ThromboVision moves to new facility
ThromboVision (Houston), a diagnostics company, has moved into a 3,000-square-foot manufacturing and headquarters facility. Within the next six weeks, the company expects to begin producing its ThromboGuide platelet function analyzer system for clinical trials. The system consists of a disposable test kit and a point-of-care analyzer.
The clinical trials will support ThromboVision's 510(k) application to the FDA and its application for CLIA waiver. A CLIA waiver enables tests to be run in non-laboratory venues, such as physicians' offices. The company will focus its first commercial tests on monitoring the effectiveness of aspirin and Plavix, two of the most widely prescribed antiplatelet medications for stroke prevention.
Sequenom back in Nasdaq compliance
Sequenom (San Diego) said it received a letter from the Listing Qualifications Panel of the Nasdaq Stock Market informing the company it had evidenced compliance with the minimum bid price requirement for continued listing on the Nasdaq National Market, as required by the panel's hearing decision of April 24.
The panel further acknowledged that it appears Sequenom has regained compliance with Nasdaq's shareholders' minimum equity requirement based on net proceeds from the company's recently announced successful raise of $33 million through a private placement of common stock and warrants.
Accordingly, the panel granted Sequenom an exception until Aug. 15 to file with the Securities and Exchange Commission, its Form 10-Q for the quarter ending June 30, evidencing shareholders' equity of at least $10 million.
The company said it expects meet the panel's requirements and to remain listed on Nasdaq.
New name for Ventiv Health
Ventiv Health (Somerset, New Jersey), a provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries, reported that at its annual meeting, held June 14, shareholders approved the official change of the company's name to inVentiv Health. Shares of inVentiv will continue to trade on Nasdaq under its current symbol VTIV.
inVentiv announced on March 14 that it was changing its corporate brand name as part of a re-branding initiative to reflect the company's expansion growth.